Research Progress of Nanovaccine in Tumor Immunotherapy

被引：0
|
作者：
Mao Jia-Rong [1 ]
Qian Ying [2 ]
Shi Guo-Ping [1 ]
Wang Jing-Jing [2 ]
Chen Yu-Gen [1 ]
机构：
[1] Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing 210029, Peoples R China
[2] Nanjing Univ Chinese Med, Coll Pharm, Nanjing 210044, Peoples R China
来源：
PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS | 2021年 / 48卷 / 10期
基金：
中国国家自然科学基金;
关键词：
nano; vaccine; tumor immunotherapy; adjuvant; targeting;
D O I：
10.16476/j.pibb.2021.0007
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
In recent years, tumor immunotherapy has become a hot spot in the field of cancer treatment. Among them, nanovaccines combining tumor vaccines and nanotechnology provide new ideas for tumor immunotherapy. Nanovaccine can realize the co-loading of vaccine and adjuvant. The intelligent nanocarriers further realize the effective targeted delivery of antigen, promote the uptake and presentation of antigen, specifically activate antigen-specific immune response and effectively kill tumor cells. This article reviews the principles, advantages, types of nano materials, and clinical efficacy of nanovaccine to provide a more reliable reference for the design of nano-vaccine in the later stage.
引用
收藏
页码：1130 / 1136
页数：7
相关论文
共 48 条
  • [1] Zheng S R, Sun K X, Zhang S W, Et al., Chinese Journal of Oncology, 41, 1, pp. 19-28, (2019)
  • [2] Klevorn L E, Teague R M., Adapting cancer immunotherapy models for the real world, Trends in Immunology, 37, 6, pp. 354-363, (2016)
  • [3] Krummel M F, Allison J P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation, J Exp Med, 182, 2, pp. 459-465, (1995)
  • [4] Gross G, Waks T, Eshhar Z., Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc Natl Acad Sci USA, 86, 24, pp. 10024-10028, (1989)
  • [5] Walunas T L, Lenschow D J, Bakker C Y, Et al., CTLA-4 can function as a negative regulator of T cell activation, Immunity, 1, 5, pp. 405-413, (1994)
  • [6] Rosenberg S A, Restifo N P., Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 6230, pp. 62-68, (2015)
  • [7] Maude S L, Barrett D, Teachey D T, Et al., Managing cytokine release syndrome associated with novel T cell-engaging therapies, Cancer Journal, 20, 2, pp. 119-122, (2014)
  • [8] Lee D W, Gardner R, Porter D L, Et al., Current concepts in the diagnosis and management of cytokine release syndrome, Blood, 124, 2, pp. 188-195, (2014)
  • [9] Jacobs I, Bast R J., The CA 125 tumour-associated antigen: a reviewoftheliterature, HumanReproduction, 4, 1, pp. 1-12, (1989)
  • [10] Wang R J, Li Y H, Geng Y D, Et al., Chinese Journal of Obstetrics and Gynecology, 54, 4, pp. 280-284, (2019)
12345